Chicago, IL – According to filings with the U.S. Securities and Exchange Commission, Paragon Biosciences is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jeffrey Aronin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Paragon Biosciences
Paragon is a life science innovator that creates, invests in and builds bioscience companies. We solve complex challenges by advancing science. Paragon focuses on four areas of life science innovation including artificial intelligence, gene therapy, synthetic biology and biopharmaceuticals. Our current portfolio includes Castle Creek Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies in development. Paragon stands at the intersection of human need, life science, and company creation.

To learn more about Paragon Biosciences, visit http://paragonbiosci.com/

Contact:
Jeffrey Aronin, Chief Executive Officer
312-847-1350
https://www.linkedin.com/in/jeffrey-aronin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved